Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States

被引：2

作者：

Layton, J. Bradley ^{[1
,8
]}

Peetluk, Lauren ^{[2
]}

Wong, Hui Lee ^{[3
]}

Jiao, Yixin ^{[4
]}

Djibo, Djeneba Audrey ^{[5
]}

Bui, Christine ^{[1
]}

Lloyd, Patricia C. ^{[3
]}

Gruber, Joann F. ^{[3
]}

Miller, Michael ^{[2
]}

Ogilvie, Rachel P. ^{[2
]}

Deng, Jie ^{[2
]}

Parambi, Ron ^{[2
]}

Song, Jennifer ^{[2
]}

Weatherby, Lisa B. ^{[2
]}

Lo, An-Chi ^{[4
]}

Matuska, Kathryn ^{[4
]}

Wernecke, Michael ^{[4
]}

Clarke, Tainya C. ^{[3
]}

Cho, Sylvia ^{[3
]}

Bell, Elizabeth J. ^{[2
]}

Seeger, John D. ^{[2
]}

Yang, Grace Wenya ^{[5
,6
]}

Illei, Dora ^{[7
]}

Forshee, Richard A. ^{[3
]}

Anderson, Steven A.

McMahill-Walraven, Cheryl N. ^{[4
]}

Chillarige, Yoganand ^{[4
]}

Amend, Kandace L. ^{[2
]}

Anthony, Mary S. ^{[1
]}

Shoaibi, Azadeh ^{[3
]}

机构：

[1] RTI Hlth Solut, Res Triangle Pk, NC USA

[2] Optum Epidemiol, Boston, MA USA

[3] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA

[4] Acumen LLC, Burlingame, CA USA

[5] CVS Hlth, Safety Surveillance & Collaborat, Blue Bell, PA USA

[6] Optum Serve, Falls Church, VA USA

[7] RTI Int, Washington, DC USA

[8] RTH Hlth Solut, 3040 East Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA

来源：

VACCINE: X | 2024年 / 16卷

关键词：

COVID-19; vaccines; Pharmacoepidemiology; Vaccine effectiveness; COVID-19-ASSOCIATED EMERGENCY-DEPARTMENT; URGENT CARE ENCOUNTERS; MESSENGER-RNA VACCINES; VISION NETWORK; SARS-COV-2; INFECTION; ADDITIONAL PRIMARY; OMICRON VARIANT; HOSPITALIZATIONS; CHILDREN; ADULTS;

D O I：

10.1016/j.jvacx.2024.100447

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: Monovalent booster/additional doses of COVID-19 vaccines were first authorized in August 2021 in the United States. We evaluated the real-world effectiveness of receipt of a monovalent booster/additional dose of COVID-19 vaccine compared with receiving a primary vaccine series without a booster/additional dose. Methods: Cohorts of individuals receiving a COVID-19 booster/additional dose after receipt of a complete primary vaccine series were identified in 2 administrative insurance claims databases (Optum, CVS Health) supplemented with state immunization information system data between August 2021 and March 2022. Individuals with a complete primary series but without a booster/additional dose were one-to-one matched to boosted individuals on calendar date, geography, and clinical factors. COVID-19 diagnoses were identified in any medical setting, or specifically in hospitals/emergency departments (EDs). Propensity score-weighted hazards ratios (HRs) and 95% confidence intervals (CI) were estimated with Cox proportional hazards models; vaccine effectiveness (VE) was estimated as 1 minus the HR by vaccine brand overall and within subgroups of variant-specific eras, immunocompromised status, and homologous/heterologous booster status. Results: Across both data sources, we identified 752,165 matched pairs for BNT162b2, 410,501 for mRNA-1273, and 11,398 for JNJ-7836735. For any medically diagnosed COVID-19, meta-analyzed VE estimates for BNT162b2, mRNA-1273, and JNJ-7836735, respectively, were: BNT162b2, 54% (95% CI, 53%-56%); mRNA1273, 58% (95% CI, 56%-59%); JNJ-7836735, 34% (95% CI, 23%-44%). For hospital/ED-diagnosed COVID19, VE estimates ranged from 70% to 76%. VE was generally lower during the Omicron era than the Delta era and for immunocompromised individuals. There was little difference observed by homologous or heterologous booster status. Conclusion: The original, monovalent booster/additional doses were reasonably effective in real-world use among the populations for which they were indicated during the study period. Additional studies may be informative in the future as new variants emerge and new vaccines become available.

引用

页数：10

共 42 条

[11]

Centers for Disease Control and Prevention, 2022, Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States

[12]

Centers for Disease Control and Prevention, 2021, Centers for disease control and prevention

[13]

CMS, 2022, COVID-19 vaccines and monoclonal antibodies

[14]

FDA, 2023, Moderna COVID-19 Vaccines

[15]

FDA, 2023, Pfizer-BioNTech COVID-19 Vaccines

[16]

Ferdinands JM, 2022, MMWR-MORBID MORTAL W, V71, P255, DOI 10.15585/mmwr.mm7107e2

[17]

Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202

[18]

Fleming-Dutra KE, 2023, MMWR-MORBID MORTAL W, V72, P177, DOI 10.15585/mmwr.mm7207a3

[19] Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance [J].

Fleming-Dutra, Katherine E. ;

Britton, Amadea ;

Shang, Nong ;

Derado, Gordana ;

Link-Gelles, Ruth ;

Accorsi, Emma K. ;

Smith, Zachary R. ;

Miller, Joseph ;

Verani, Jennifer R. ;

Schrag, Stephanie J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (22) :2210-2219

[20]

Funk Michele Jonsson, 2014, Curr Epidemiol Rep, V1, P175

← 1 2 3 4 5 →